Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-assisted psychotherapy for methamphetamine use disorder
ACTRN12626001100381Phase 2Not yet recruiting
- Sponsor
- University of New South Wales
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of psilocybin in methamphetamine use disorder (MUD) (2 arms), sponsored by University of New South Wales. Primary endpoint: Number of days of methamphetamine use in prior 28 days. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
psilocybin
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on ACTRN12626001100381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626001100381.